| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhang,Li-Qi | Chairman | 9.22% | |
| HONG QI INTERNATIONAL INVESTMENT CO., LTD. | Director | 8.77% | |
| Li,Zhong-Liang | Director | 36.32% | GOLDFIX INVESTMENTS LTD. |
| Chen,Ming-Tong | Director | 0.04% | |
| Zhang,Sen-Xiong | Independent Director | 0.00% | |
| Hou,Li-Ren | Independent Director | 0.00% | |
| Chen,Qun-Zhi | Independent Director | 0.00% |
Change Company Name to DV Biomed Co., Ltd.
2024/05/31
Change Company Name to LITONG BIOMEDICAL TECHNOLOGY CO., LTD. (FORMER NAME: XIANGYU BIOMEDICAL TECHNOLOGY CO., LTD.)
2022/07/14
Change Company Name to DV Biomed Co., Ltd.
2020/06/29
Change Person in Charge to Zhang,Li-Qi
2020/01/16
Change Capital to 800,000,000
2019/04/15
Change Capital to 600,000,000
2015/06/26
Change Person in Charge to Cai,Jia-Ju
2013/01/10
Change Capital to 250,000,000
2012/11/19
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 248,712 | 1,538,352 | 1,871,224 |
| Operating cost | 57,336 | 774,075 | 829,029 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 191,376 | 764,277 | 1,042,195 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 191,376 | 764,277 | 1,042,195 |
| Operating expenses | 160,377 | 590,728 | 661,482 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 30,999 | 173,549 | 380,713 |
| Non-operating income and expenses | 5,252 | 14,874 | -23,398 |
| Net profit (loss) before tax | 36,251 | 188,423 | 357,315 |
| Income tax expense (benefits) | 8,227 | 35,396 | 76,057 |
| Net profit (loss) of ongoing business for the current period | 28,024 | 153,027 | 281,258 |
| Profit (loss) of closed units | 0 | 9,883 | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 28,024 | 162,910 | 281,258 |
| Other comprehensive profit (loss), net | 3,983 | -1,565 | 1,630 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 32,007 | 161,345 | 282,888 |
| Net profit (loss) attributable to owners of parent company | 25,266 | 162,910 | 281,258 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | 2,758 | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | 0 |
| Comprehensive profit (loss) attributable to owners of parent company | 29,249 | 161,345 | 282,888 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | 2,758 | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | 0 |
| Basic earnings per share (yuan) | 1 | 2 | 4 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -1,275 | 332,339 | 522,581 |
| Net cash inflows (outflows) from investing activities | -28,399 | -178,248 | -198,008 |
| Net cash inflow (outflow) from financing activities | 24,386 | -388,137 | -426,008 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1,816 | 4,215 | 644 |
| Increase (decrease) in cash and cash equivalents in the current period | -3,472 | -229,831 | -100,791 |
| Beginning balance of cash and cash equivalents | 226,530 | 456,827 | 557,618 |
| Ending balance of cash and cash equivalents | 223,058 | 226,996 | 456,827 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 451,684 | 615,954 | 1,005,770 |
| Non-current asset | 165,983 | 1,196,692 | 1,040,567 |
| Total asset | 617,667 | 1,812,646 | 2,046,337 |
| Current liability | 86,785 | 392,894 | 480,765 |
| Non-current liability | 30,323 | 372,980 | 420,458 |
| Total liability | 117,108 | 765,874 | 901,223 |
| share capital | 208,611 | 604,465 | 614,465 |
| Equity - secruity token | - | - | - |
| capital reserve | 12,960 | 190,279 | 211,509 |
| retained earning | 302,643 | 307,273 | 431,353 |
| Other equity | -9,107 | -13,090 | -11,525 |
| Treasury stock | -14,548 | -42,155 | -100,688 |
| Total equity attributable to owners of parent company | 500,559 | 1,046,772 | 1,145,114 |
| Equity attributable to former owner of business combination under common control | 0 | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 500,559 | 1,046,772 | 1,145,114 |
| Share capital awaiting retirement (unit: share) | - | - | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 226,051 | 655,000 | 1,655,000 |
| Net asset value per share | 24 | 17 | 19 |
